SHALLCROSS STEVEN A (CEO and CFO) purchased 5.9% of their position (14K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $9.7K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 6/8/2023ACC: 0001104659-23-069136
DirectorOfficer· CEO and CFO
Since Dec 2018
+14K
Net shares
Net buyer
$9.7K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
14K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+14K
Price / share
$0.69
Trade value
$9.70K
% of position
5.9%
6/7/2023
236K→250K
Total
Net shares
+14K
Net value
$9.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/7/2023 | P · Purchase | +14K | $0.69 | $9.70K | 5.9% | 236K | 250K |
| Total | +14K | $9.70K | ||||||
Derivative Transactions0
No derivative transactions reported